Date：29 July (Friday)
Time: 10:40 – 12:10 (GMT+8)
WuXi Advanced Therapies Business Unit (ATU)
Adeno-Associated Virus (AAV) and Lenti Viral Vector (LVV) have been the key work horses for gene therapies and gene-mediated cell therapies. The current standard platforms for producing AAV and LVV are mainly based on plasmid-dependent transient expression which typically encounters the limitation of scalability, high cost of plasmids, lower viral yield and less percentage of infectious VV. Lately, the plasmid-independent AAV production platform, TessaTM, and LVV production platform, LentiVEX-StableTM, have been developed by WuXi Advanced Therapies Business Unit (ATU). These transformational VV production platforms significantly improve the yield and the percentage of infectious VV as well as overcome the limitation of scalability. These improvements will significantly reduce the cost of goods for VV production, and thus enable the development of cell and gene therapies with broader patient access in the future.